SLC25A5 and neoplasm: As shown in Figures 4C and D, the tumor cells treated with the combination therapy showed significantly higher expression levels of Fas than tumor cells treated with ANT2 shRNA or I-131 (19.2±1.6%, 22.7±2.5% and 44.1±4.4%, ANT2 shRNA, I-131, combination, respectively; P<0.05, control or scramble versus ANT2 shRNA or I-131, P<0.05, ANT2 shRNA or I-131 versus combination).